// App-Quantinova.ai

: Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial

Researchers

Presenter

  • Richard Furie

Principal Investigators

  • Nicholas Jones

  • Pascal Guibord

  • Joshua Galanter

  • Chin Lee

  • Anna McGregor

  • Balazs Toth

  • Julie Rae

  • Olivia Hwang

  • Pedro Miranda

  • Viviane de Souza

  • Juan Jaller-Raad

  • Anna Maura Fernandes

  • Rodrigo Garcia Salinas

  • Leslie Chinn

  • Michael Townsend

  • Alyssa Morimoto

  • Katie Tuckwell

Medical Centers

  • Kings College London, London, United Kingdom

  • Northwell Health, Great Neck, NY

  • Genentech, Inc., South San Francisico, CA

  • Hoffmann-La Roche Ltd, Mississauga, ON, Canada

  • Genentech, Inc., SOUTH SAN FRANCISCO

  • Centro De Estudios Reumatologicos, Santiago, Chile

  • Centro Mineiro de Pesquisas, Juiz de Fora, Minas Gerais, Brazil

  • Centro de Reumatologia y Ortopedia, Barranquilla, Colombia

  • Mario Covas Hospital, Santo Andre, Brazil

  • Hospital Italiano de la Plata, la Plata, Buenos Aires, Argentina

  • Genentech, Inc., South San Francisico, CA

  • Genentech, Inc., South San Francisico, CA

Locations

  • United Kingdom

  • United States

  • Canada

  • Chile

  • Brazil

  • Colombia

  • Argentina

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Fenebrutinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacodynamics

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved